These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 15344963

  • 1. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L, Ehrich JH, Offner G.
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N.
    Transplantation; 2011 Sep 15; 92(5):550-6. PubMed ID: 21709602
    [Abstract] [Full Text] [Related]

  • 4. What is the intrapatient variability of mycophenolic acid trough levels?
    Todorova EK, Huang SH, Kobrzynski MC, Filler G.
    Pediatr Transplant; 2015 Nov 15; 19(7):669-74. PubMed ID: 26201386
    [Abstract] [Full Text] [Related]

  • 5. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C, Barrail-Tran A, Hemerziu B, Habes D, Taburet AM, Debray D, Furlan V.
    Liver Transpl; 2011 Oct 15; 17(10):1152-8. PubMed ID: 21695772
    [Abstract] [Full Text] [Related]

  • 6. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Jan 15; 47(1):88-94. PubMed ID: 11148182
    [Abstract] [Full Text] [Related]

  • 7. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb 15; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM, Brown NW, Itsuka T, Gonde CE, Adams JE, Heaton ND, Tredger JM, Mieli-Vergani G, Dhawan A.
    Liver Transpl; 2003 Apr 15; 9(4):383-8. PubMed ID: 12682891
    [Abstract] [Full Text] [Related]

  • 9. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity.
    Filler G, Gellermann J, Zimmering M, Mai I.
    Transpl Int; 2000 Apr 15; 13(3):201-6. PubMed ID: 10935703
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM.
    J Heart Lung Transplant; 2001 Oct 15; 20(10):1035-43. PubMed ID: 11595558
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug 15; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis.
    Benz K, Plank C, Griebel M, Montoya C, Dötsch J, Klare B.
    Pediatr Transplant; 2006 May 15; 10(3):331-6. PubMed ID: 16677357
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.
    Transplant Rev (Orlando); 2011 Apr 15; 25(2):47-57. PubMed ID: 21190834
    [Abstract] [Full Text] [Related]

  • 18. Developmental changes of MPA exposure in children.
    Yoo EC, Alvarez-Elías AC, Todorova EK, Filler G.
    Pediatr Nephrol; 2016 Jun 15; 31(6):975-82. PubMed ID: 26743220
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug 15; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.